Intramuscular injection of [6-D-tryptophan]-luteinizing hormone-releasing hormone ([D-Trp6]LH-RH) inmicrocapsules of poly(DL-lactide-co-glycolide), designed to release a controlled dose of the peptide over a 30-day period, decreased the weights of androgen-dependent Dunning prostate tumors in rats and suppressed serum testosterone levels more effectively than daily subcutaneous administration of equivalent or double doses of unencapsulated last from a few minutes to several hours. These modes of administration, with fluctuating blood levels of the peptide, may not achieve the optimal pharmacological effects. Consequently, higher-dosage regimens and greater frequency of administration may be needed to obtain these effects. A peptide administered by a controlled delivery system that would lead to a constant release over a prolonged period of time could provide a continuous biological effect. Recently, a polymer of poly(DL-lactide-co-glycolide) (PLG) has been used to formulate microcapsules with steroids for long-acting contraceptive delivery systems (22)(23)(24)
MATERIALS AND METHODSMale (Copenhagen x Fisher) F1 rats bearing the androgendependent well-differentiated R3327H Dunning rat prostate adenocarcinoma were provided by Norman Altman (Papanicolaou Cancer Research Institute, Miami, FL). Approximately 150 days after the transplantation, the tumors were palpable and the experiment began. Tumors were measured weekly with microcalipers and tumor volumes were calculated as previously described (12, 13